U.S. IVD & LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Application (Ankylosing Spondylitis, Alopecia Areata, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Psoriasis), By Technology, And Segment Forecasts, 2018 - 2024

Table of Contents

Chapter 1 Research Methodology
                    1.1 Information Procurement
                         1.1.1 Purchased database:
                         1.1.2 GVR’s internal database
                    1.2 Primary Research:
                         1.2.1 List of Primary Sources Include:
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
                    4.1 Market Segmentation & Scope
                         4.1.1 Market Driver Analysis
                         4.1.2 Growing Prevalence of Autoimmune Diseases
                         4.1.3 Increasing Demand for Personalized Medicine
                         4.1.4 Introduction of Technological Advancements
                    4.2 Market Restraint Analysis
                         4.2.1 Low research budget for autoimmune diseases
                    4.3 Key Opportunities Prioritized
                    4.4 U.S. Lab Test IVD for Autoimmune Disease Diagnostics Market- SWOT Analysis, by Factor
                    4.5 Industry Analysis - Porter’s
                    4.6 Technology Trends
                    4.7 Competitive Analysis/Heat Map Analysis 2015
Chapter 5 Market Categorization 1: Application Estimates & Trend Analysis
                    5.1 U.S. Lab Test IVD for Autoimmune Disease Diagnostics Market: Application Movement Analysis
                    5.2 U.S. Lab Test LDT for Autoimmune Disease Diagnostics Market: Application Movement Analysis
                    5.3 Addison’s Disease
                         5.3.1 U.S. lab test IVD for Addison’s disease diagnostics market, 2013 - 2024 (USD Million)
                         5.3.2 U.S. lab test LDT for Addison’s disease diagnostics market, 2013 - 2024 (USD Million)
                    5.4 Ankylosing Spondylitis (AS)
                         5.4.1 U.S. lab test IVD for AS diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.4.2 U.S. lab test LDT for AS diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                    5.5 Alopecia Areata
                         5.5.1 U.S. lab test IVD for alopecia areata diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.5.2 U.S. lab test LDT for alopecia areata diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                    5.6 Rheumatoid Arthritis (RA)
                         5.6.1 U.S. lab test IVD for RA diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.6.2 U.S. lab test LDT for RA diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                    5.7 Systemic Lupus Erythematosus (SLE)
                         5.7.1 U.S. lab test IVD for SLE diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.7.2 U.S. lab test LDT for systemic lupus erythematosus diagnostics market, 2013 - 2024 (USD Million)
                    5.8 Systemic Sclerosis
                         5.8.1 U.S. lab test IVD for systemic sclerosis diagnostics market estimates, 2013 - 2024 (USD Million)
                         5.8.2 U.S. lab test LDT for systemic sclerosis diagnostics market estimates, 2013 - 2024 (USD Million)
                    5.9 Psoriasis
                         5.9.1 U.S. lab test IVD for psoriasis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.9.2 U.S. lab test LDT for psoriasis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                    5.10 Antiphospholipid Antibody Syndrome (APS)
                         5.10.1 U.S. lab test IVD for APS diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.10.2 U.S. lab test LDT for APS diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                    5.11 Diabetes Type 1 (T1D)
                         5.11.1 U.S. lab test IVD for diabetes type 1 diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.11.2 U.S. lab test LDT for diabetes type 1 diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                    5.12 Crohn’s Disease
                         5.12.1 U.S. lab test IVD for Crohn’s disease diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.12.2 U.S. lab test LDT for Crohn’s disease diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                    5.13 Ulcerative Colitis
                         5.13.1 U.S. lab test IVD for ulcerative colitis diagnostics market estimates, 2013 - 2024 (USD Million)
                         5.13.2 U.S. lab test LDT for ulcerative colitis diagnostics market estimates, 2013 - 2024 (USD Million)
                    5.14 Narcolepsy
                         5.14.1 U.S. lab test IVD for narcolepsy diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.14.2 U.S. lab test LDT for narcolepsy diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                    5.15 Multiple Sclerosis (MS)
                         5.15.1 U.S. lab test IVD for multiple sclerosis diagnostics market estimates, 2013 - 2024 (USD Million)
                         5.15.2 U.S. lab test LDT for multiple sclerosis diagnostics market estimates, 2013 - 2024 (USD Million)
                    5.16 Uveitis
                         5.16.1 U.S. lab test IVD for uveitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.16.2 U.S. lab test LDT for uveitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                    5.17 Others
                         5.17.1 U.S. lab test IVD for others diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         5.17.2 U.S. lab test LDT for others diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Technology Estimates & Trend Analysis
                    6.1 U.S. Lab Test IVD for Autoimmune Disease Diagnostics Market: Technology Movement Analysis
                    6.2 U.S. Lab Test LDT for Autoimmune Disease Diagnostics Market: Technology Movement Analysis
                    6.3 Immunoassays
                         6.3.1 U.S. lab test IVD for Immunoassays market estimates and forecasts, 2013 - 2024 (USD Million)
                         6.3.2 U.S. lab test LDT for Immunoassays market estimates and forecasts, 2013 - 2024 (USD Million)
                    6.4 Clinical Chemistry
                         6.4.1 U.S. lab test IVD for clinical chemistry market estimates and forecasts, 2013 - 2024 (USD Million)
                         6.4.2 U.S. lab test LDT for clinical chemistry market estimates and forecasts, 2013 - 2024 (USD Million)
                    6.5 Hematology
                         6.5.1 U.S. lab test IVD for hematology market estimates and forecasts, 2013 - 2024 (USD Million)
                         6.5.2 U.S. lab test LDT for hematology market estimates and forecasts, 2013 - 2024 (USD Million)
                    6.6 Coagulation
                         6.6.1 U.S. lab test IVD for coagulation market estimates and forecasts, 2013 - 2024 (USD Million)
                         6.6.2 U.S. lab test LDT for coagulation market estimates and forecasts, 2013 - 2024 (USD Million)
                    6.7 Microbiology
                         6.7.1 U.S. lab test IVD for microbiology market estimates and forecasts, 2013 - 2024 (USD Million)
                         6.7.2 U.S. lab test LDT for microbiology market estimates and forecasts, 2013 - 2024 (USD Million)
                    6.8 Molecular Diagnostics
                         6.8.1 U.S. lab test IVD for molecular diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
                         6.8.2 U.S. lab test LDT for molecular diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 7 Competitive Landscape
                    7.1 Company Profiles
                         7.1.1 Abbott
                               7.1.1.1 Company overview
                               7.1.1.2 Financial performance
                               7.1.1.3 Product benchmarking
                               7.1.1.4 Strategic initiatives
                         7.1.2 Roche Diagnostics
                               7.1.2.1 Company overview
                               7.1.2.2 Financial performance
                               7.1.2.3 Product benchmarking
                               7.1.2.4 Strategic initiatives
                         7.1.3 Siemens Healthcare GmbH
                               7.1.3.1 Company Overview
                               7.1.3.2 Financial Performance
                               7.1.3.3 Product Benchmarking
                               7.1.3.4 Strategic Initiatives
                         7.1.4 Beckman Coulter, Inc.
                               7.1.4.1 Company Overview
                               7.1.4.2 Financial Performance
                               7.1.4.3 Product Benchmarking
                               7.1.4.4 Strategic Initiatives
                         7.1.5 SQI Diagnostics
                               7.1.5.1 Company Overview
                               7.1.5.2 Financial Performance
                               7.1.5.3 Product Benchmarking
                               7.1.5.4 Strategic Initiatives
                         7.1.6 Alere
                               7.1.6.1 Company Overview
                               7.1.6.2 Financial Performance
                               7.1.6.3 Product Benchmarking
                               7.1.6.4 Strategic Initiatives
                         7.1.7 Bio-Rad Laboratories, Inc.
                               7.1.7.1 Company Overview
                               7.1.7.2 Financial Performance
                               7.1.7.3 Product Benchmarking
                               7.1.7.4 Strategic Initiatives
                         7.1.8 Becton, Dickinson & Company
                               7.1.8.1 Company Overview
                               7.1.8.2 Financial Performance
                               7.1.8.3 Product Benchmarking
                               7.1.8.4 Strategic Initiatives
                         7.1.9 Omega Diagnostics Group PLC
                               7.1.9.1 Company Overview
                               7.1.9.2 Financial Performance
                               7.1.9.3 Product Benchmarking
                         7.1.10 Thermo Fisher Scientific Inc.
                               7.1.10.1 Company Overview
                               7.1.10.2 Financial Performance
                               7.1.10.3 Product Benchmarking
                               7.1.10.4 Strategic Initiatives
                         7.1.11 Mayo Medical Laboratories
                               7.1.11.1 Company Overview
                               7.1.11.2 Financial Performance
                               7.1.11.3 Product Benchmarking
                               7.1.11.4 Strategic Initiatives
                         7.1.12 Oklahoma Medical Research Foundation (OMRF)
                               7.1.12.1 Company Overview
                               7.1.12.2 Financial Performance
                               7.1.12.3 Product Benchmarking
                         7.1.13 Moleculera Labs
                               7.1.13.1 Company Overview
                               7.1.13.2 Financial Performance
                               7.1.13.3 Product Benchmarking
                               7.1.13.4 Strategic Initiatives

List of Tables

TABLE 1 List of Autoimmune Diseases and its impact on the U.S. population
TABLE 2 Comparative Analysis of NIH funding

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market Summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 Key opportunities prioritized
FIG. 10 Endoscopy Devices-PESTEL Analysis
FIG. 11 Porter’s Five Forces Analysis
FIG. 12 Competitive Analysis/Heat Map Analysis 2015
FIG. 13 U.S. lab test IVD for autoimmune disease diagnostics market application outlook key takeaways
FIG. 14 U.S. lab test LDT for autoimmune disease diagnostics market application outlook key takeaways
FIG. 15 U.S. lab test IVD for autoimmune disease diagnostics market: Application movement analysis
FIG. 16 U.S. lab test LDT for autoimmune disease diagnostics market: Application movement analysis
FIG. 17 U.S. lab test IVD for Addison’s disease diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 18 U.S. lab test LDT for Addison’s disease diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 19 U.S. lab test IVD for ankylosing spondylitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 20 U.S. lab test LDT for ankylosing spondylitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 21 U.S. lab test IVD for alopecia areata diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 22 U.S. lab test LDT for alopecia areata diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 23 U.S. lab test IVD for rheumatoid arthritis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 24 U.S. lab test LDT for rheumatoid arthritis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 25 U.S. lab test IVD for systemic lupus erythematosus diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 26 U.S. lab test LDT for systemic lupus erythematosus diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 27 U.S. lab test IVD for systemic sclerosis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 28 U.S. lab test LDT for systemic sclerosis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 29 U.S. lab test IVD for psoriasis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 30 U.S. lab test LDT for psoriasis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 31 U.S. lab test IVD for antiphospholipid antibody syndrome diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 32 U.S. lab test LDT for antiphospholipid antibody syndrome diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 33 U.S. lab test IVD for diabetes type 1 diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 34 U.S. lab test LDT for diabetes type 1 diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 35 U.S. lab test IVD for crohn’s disease diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 36 U.S. lab test LDT for crohn’s disease diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 37 U.S. lab test IVD for ulcerative colitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 38 U.S. lab test LDT for ulcerative colitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 39 U.S. lab test IVD for narcolepsy diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 40 U.S. lab test LDT for narcolepsy diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 41 U.S. lab test IVD for multiple sclerosis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 42 U.S. lab test LDT for multiple sclerosis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 43 U.S. lab test IVD for uveitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 44 U.S. lab test LDT for uveitis diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 45 U.S. lab test IVD for others diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 46 U.S. lab test LDT for others diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 47 U.S. lab test IVD for autoimmune disease diagnostics: Technology outlook key takeaways
FIG. 48 U.S. lab test LDT for autoimmune disease diagnostics: Technology outlook key takeaways
FIG. 49 U.S. lab test IVD for autoimmune disease diagnostics market: Technology type movement analysis
FIG. 50 U.S. lab test LDT for autoimmune disease diagnostics market: Technology type movement analysis
FIG. 51 U.S. lab test IVD for Immunoassays market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 52 U.S. lab test IVD for Immunoassays market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 53 U.S. lab test IVD for clinical chemistry market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 54 U.S. lab test LDT for clinical chemistry market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 55 U.S. lab test IVD for hematology market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 56 U.S. lab test LDT for hematology market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 57 U.S. lab test IVD for coagulation market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 58 U.S. lab test LDT for coagulation market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 59 U.S. lab test IVD for microbiology market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 60 U.S. lab test LDT for microbiology market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 61 U.S. lab test IVD for molecular diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 62 U.S. lab test LDT for molecular diagnostics market estimates and forecasts, 2013 - 2024 (USD Million)